Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S.
Food and Drug Administration for its Abbreviated New Drug Application Hydrocortisone Tablets USP, 5 mg, 10mg, and 20mg. Aurobindo Pharma’s Hydrocortisone Tablets USP are an AB-rated generic equivalent to the reference listed drug (RLD), CORTEF tablets manufactured by Pharmacia and Upjohn Co.
Hydrocortisone Tablets are indicated for the following conditions:
1. Endocrine Disorders
2. Rheumatic Disorders
3. Collagen Diseases
4. Dermatologic Diseases
5. Allergic States
6. Ophthalmic Diseases
7. Respiratory Diseases
8. Hematologic Disorders
9. Neoplastic Diseases
10. Edematous States
11. Gastrointestinal Diseases
Hydrocortisone Tablets USP has an estimated market size of US $35.1 million for the twelve months ending May 2023, as per IQVIA.
